Company intelligence / Profile preview

IMMUNOSPEC

Ghent, East Flanders, Belgium

Ownership: Private
Development stage: Other

Overview

ImmunoSpec is a specialized biotechnology company focused on immunopeptidomics and the characterization of MHC-associated peptides. The company utilizes advanced mass spectrometry techniques to identify and quantify the repertoire of peptides presented by Human Leukocyte Antigens (HLA) on the surface of cells. This technology is critical for the development of personalized cancer vaccines, T-cell therapies, and the assessment of drug immunogenicity. ImmunoSpec provides high-resolution mapping of the immunopeptidome to support pharmaceutical and biotech partners in target discovery and lead optimization.

Therapeutic areas: Infectious DiseasesOncologyImmunology
Modalities: ImmunopeptidomicsMass spectrometryProteomics
Industry: Drug Discovery Services

Beyond the preview

Go deeper on IMMUNOSPEC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMMUNOSPEC.

Explore the full profile